NTRK1 and non-small cell lung carcinoma: Repotrectinib is a ROS1/TRK/ALK Inhibitor that was granted breakthrough therapy designation (BTD) for treating ROS1-postive or NTRK-positive NSCLC based on the results from TRIDENT-1 trial [38,39].